Ryanair Profit Slumps in Q3 After Italy Antitrust Fine Despite Revenue Growth 
Anthropic Raises 2026 Revenue Outlook by 20% but Delays Path to Profitability 
Micron to Expand Memory Chip Manufacturing Capacity in Singapore Amid Global Shortage 
LVMH Succession Uncertainty Raises Governance Concerns Among Shareholders 
Sam Altman Criticizes ICE Enforcement as Corporate Leaders Call for De-Escalation 
Microsoft Wins Approval to Build 15 New Data Centers in Wisconsin 
Boeing Posts Fourth-Quarter Profit on Jeppesen Sale Despite Ongoing Unit Losses 
SoftBank Shares Surge as It Eyes Up to $30 Billion New Investment in OpenAI 
Tesla Loses Ground in Europe as BYD Accelerates EV Market Share in 2025 
Hyundai Motor Shares Slide After Trump Signals Higher U.S. Tariffs on South Korean Goods 
Alibaba-Backed Moonshot AI Unveils Kimi K2.5 to Challenge China’s AI Rivals 
Citigroup Faces Lawsuit Over Alleged Sexual Harassment by Top Wealth Executive 
Trump Lawsuit Against JPMorgan Signals Rising Tensions Between Wall Street and the White House 
China Approves First Import Batch of Nvidia H200 AI Chips Amid Strategic Shift 
EXTON, Pa., May 17, 2017 -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that John Maslowski, Chief Executive Officer, will present at the inaugural Cell & Gene Exchange 2017 on Monday, May 22 at 2:00 pm EDT at the Ronald Reagan Building in Washington, D.C. In addition, Mr. Maslowski will participate in a roundtable discussion, “Best Practices for Partnering with Disease Foundations and Patient Groups,” on Monday, May 22 at 3:15 p.m. EDT.
A live webcast of Mr. Maslowski’s presentation and the roundtable discussion will be available under the investor relations section of Fibrocell’s website at www.fibrocell.com/investors/events and archived for 30 days.
Co-produced by the Alliance for Regenerative Medicine and the EBD Group and held in partnership with Global Genes, this event is the only partnering conference that brings together the regulatory, business and patient advocacy communities across the cell and gene therapy sectors.
About Fibrocell
Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue. Fibrocell’s most advanced product candidate, FCX-007, is the subject of a Phase 1/2 clinical trial for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is in pre-clinical development of FCX-013, its product candidate for the treatment of linear scleroderma. Fibrocell’s gene therapy portfolio is being developed in collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology. For more information, visit http://www.fibrocell.com or follow Fibrocell on Twitter at @Fibrocell.
Trademarks
Fibrocell, the Fibrocell logo and Fibrocell Science are trademarks of Fibrocell Science, Inc. and/or its affiliates. All other names may be trademarks of their respective owners.
Investor & Media Relations Contact: Karen Casey 484.713.6133 [email protected]
